Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;9(5):3507-3517.
doi: 10.21037/tcr.2020.03.70.

MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8

Affiliations

MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8

Pengfei Shen et al. Transl Cancer Res. 2020 May.

Erratum in

Abstract

Background: Tumor-derived interleukin-8 (IL-8) promotes tumorigenesis and progression of prostate cancer (PCa). MicroRNAs (miRNAs) are noncoding regulatory RNAs and their dysregulation is known to be implicated in carcinogenesis. However, the post-transcriptional mechanism of IL-8 via miRNAs is not fully understood. This study was intended to investigate whether miR-106a could affect the progression of PCa via targeting IL-8 or not.

Methods: Using bioinformatics analysis, we postulated that IL-8 might be post-transcriptionally regulated by miR-106a. This was validated by dual reporter gene assays that miR-106a could bind to the predicted site of IL-8 mRNA. To determine the biological effects of miR-106a on PCa cells (PC-3 and DU145), MTT, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), migration and invasion assays were performed.

Results: We found that miR-106a was barely expressed in PCa cells, whereas IL-8 was aberrantly upregulated. Elevated miR-106a could reduce IL-8 expression by directly binding the 3'-UTR of IL-8. Overexpression of miR-106a in PCa cells triggered cell apoptosis and suppressed cell proliferation, migration, and invasion.

Conclusions: This research showed that miR-106a could function as a tumor-suppressor by decreasing IL-8 levels in PCa.

Keywords: Prostate cancer (PCa); interleukin-8 (IL-8); miR-106a; progression.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2020.03.70). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The expression levels of IL-8 and miR-106a in PC-3, DU145, LNCaP, and RWPE-1. RT-PCR (A) and Q-PCR (C) showed the differential expression of IL-8 mRNA in four cell lines. Western blot analysis (B,D) showed the differential expression of IL-8 protein expression levels in four cell lines. RT-PCR (E) and Q-PCR (F) demonstrated the differential expression of miR-106a in four cell lines. (C,D) Compared to RWPE-1; (F) compared to PC-3. Double asterisks indicate P<0.001.
Figure 2
Figure 2
The effects of artificial miR-106a over-expression on IL-8 in PC-3 and DU145 cells. Homogenous green fluorescence protein expression (A,B), RT-PCR (C) and Q-PCR (E) demonstrated the differential expression of miR-106a expression following infected with Ad-miR-106a or Ad-control in PC-3 and DU145 cells. Western blot analysis (D) and immunocytochemistry (F) showed the changes in IL-8 protein levels following transfected with Ad-miR-106a or Ad-control in PC-3 and DU145 cells. The bar within the picture, 50 µm. Double asterisks indicate P<0.001.
Figure 3
Figure 3
Identifying the seed sequences of miR-106a in the IL-8 3'-UTR by dual reporter gene assays. The potential seed sequences of miR-106a were predicted in the 593-600, not on the IL-8 3'-UTR (A). After artificial over-expression of miR-106a (pre-transfected with luciferase reporter vectors) in PC-3 cells, the reporter gene activity (represented by relative luciferase activity) was significantly decreased when PGL3-IL-8 was present in the construct, whereas it was obviously restored when PGL3-Mut or PGL3-Del present. Expression of Ad-miR-106a alone (without seed sequences present) or PGL3-IL-8 (without infection of Ad-miR-106a) had no effect on reporter gene activity (B). A single asterisk indicates P<0.05.
Figure 4
Figure 4
The effects of miR-106a over-expression on cell proliferation and apoptosis. MTT assay showed that proliferation was significantly inhibited in PC-3 (compared to Ad-con) and DU145 (compared to Ad-con) cells after miR-106a overexpression (A), blank: normal PC-3 or DU-145 cells. TUNEL assay demonstrated that increased apoptosis following up-regulated miR-106a in PC-3 and DU145 cells (B). Cells were stained by Streptavidin-HRP and Diaminobenzidine (DAB). The bar within the picture, 50 µm. Double asterisks indicate P<0.001.
Figure 5
Figure 5
The effects of miR-106a overexpression on migration and invasion in the transwell culture system. The migration function of PC-3 (A) and DU145 (B) (compared to Ad-con) cells was significantly inhibited after miR-106a overexpression. The invasion capability of PC-3 (C) and DU145 (D) (compared to Ad-con) cells was significantly restrained following miR-106a overexpression. Cells were stained by methylrosanilnium chloride solution. The bar within the picture. A single asterisk indicates P<0.05. Double asterisks indicate P<0.001.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. 10.1016/j.cell.2011.02.013 - DOI - PubMed
    1. Liu Q, Li A, Tian Y, et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev 2016;31:61-71. 10.1016/j.cytogfr.2016.08.002 - DOI - PMC - PubMed
    1. Zhi F, Chen X, Wang S, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 2010;46:1640-9. 10.1016/j.ejca.2010.02.003 - DOI - PubMed
    1. Sun X, Cheng G, Hao M, et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010;29:709-22. 10.1007/s10555-010-9256-x - DOI - PMC - PubMed